Cost-Effectiveness Analysis of Pharmacogenomics-Guided Versus Standard Dosing of Warfarin in Patients with Mechanical Prosthetic Heart Valve.

Homa Hemati Marzieh Nosrati Mandana HasanzadParham RahmaniSoroush FarimanMohadese SarabiSepideh ShirvaniParham Sadeghipour Shekoufeh Nikfar

Published in: Iranian journal of pharmaceutical research : IJPR (2024)

Warfarin dosing with pharmacogenomics testing is currently not cost-effective. However, if the cost of genotyping tests decreases to $118, the ICER would become cost-effective.

Keyphrases

atrial fibrillation
direct oral anticoagulants
venous thromboembolism
oral anticoagulants
adverse drug
clinical decision support
aortic valve
mitral valve
heart failure
genome wide
high throughput
aortic stenosis
emergency department
genetic diversity
drug induced